Amgen (AMGN)
$224.84
1.89 (0.85%)
AMGN Stock Quote Delayed 15 Minutes
Previous Close
$224.84
Market Cap
148.78B
PE Ratio
71.38
EPS
3.15
Volume (Avg. Vol.)
2.10M
Day's Range
222.85 - 226.70
52-Week Range
166.30 - 244.99
Dividend & Yield
5.28 (2.35%)
AMGN Stock Predictions, Articles, and Amgen News
U.S. Cannabis Stocks Will Make Cheap, Smart Buys in 2020
Matt McCall predicts that 2020 will be a better year for U.S. cannabis stocks. He's also calling for a big rally in bitcoin.
Stock Market Today: New Highs; Buy Micron, Nvidia?
Goldman Sachs analysts came out with three conviction buys on Monday. Here's what else happened in the stock market today.
This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma
Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.
2020 Election Could Hurt Amgen Stock’s Healthy Dividend
The biggest risk to Amgen stock comes from health reform that might limit the number of drugs insurers pay for, creating price competition.
Amgen to Buy Celgene’s Otezla for $13.4B: Is the Deal Good for Amgen Stock?
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY
Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.
Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
Wednesday’s Vital Data: Amgen, American Airlines and Apple
Options trading was buzzing on Tuesday, with Amgen, American Airlines and Apple all making notable moves. Here are the metrics that matter moving forward.
9 Catalysts That Will Drive Chinese Biotech Stocks Much Higher
Matt McCall is extremely bullish on China and the big opportunities in several sectors, but Chinese biotech stocks top his list.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
